Cortexyme announces pipeline update and anticipated 2022 milestones

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided a business update and announced key milestones for 2022. christopher lowe, cortexyme's interim chief executive officer, chief operating officer, and chief financial officer, said, “cortexyme is committed to following the evidence as we identify the
QNCX Ratings Summary
QNCX Quant Ranking